Physician profile
Kristin Stringer
NPI 1679001259
$9,264.31
in general payments reported to CMS, 2019-2025
56 companies · $1,932 in 2025
The $1,932 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,819 · 2022: $1,589 · 2023: $1,884 · 2024: $2,041 · 2025: $1,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,379 · Education: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,379.05 |
| Education | $477.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,446.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,324.81 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $838.04 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $472.71 | 2021-2025 | |
| Amgen INC. | $469.98 | 2022-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $362.57 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.12 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Edwards Lifesciences Corporation | $309.32 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Radius Health, INC. | $279.80 | 2021-2025 | Tymlos |
| Glaxosmithkline, LLC. | $261.77 | 2021-2025 | Shingrix, Trelegy Ellipta, Bexsero |
| Teva Pharmaceuticals USA, INC. | $200.23 | 2023-2025 | Ajovy, Austedo |
| Medtronic, INC. | $194.61 | 2021-2024 | Intellis Adaptivestim, Micra |
| Nestle Healthcare Nutrition INC. | $187.93 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.54 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $183.54 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.